



Bordetella pertussis Epidemiology and diagnostic tools in Belgium



Denis Piérard



Universitair Ziekenhuis Brussel



Vrije Universiteit Brussel



DIAGNOSTIC TESTS

PCR	+++	+++	+++	++	+				
Culture	+++	+++	++	+					
DFA	++	++	+	+					
Serology					+	++	++		

COMPLICATIONS

Apnea, bradycardia	+++	+++	++	+	+				
Seizures, encephalopathy	++	+++	++	+	+				
2° Pneumonia, atelectasis		+++	++	+					
Malnutrition, apathy			++	+++	+++	++	++	++	+

Clinical manifestations

- Classical pertussis (mainly in unimmunized toddlers and children)
 - 3 stages, after incubation of 7 to 10 days (range 5 to 21 days)
 - Catarrhal: nondistinctive catarrhal symptoms
 - Paroxysms of cough with inspiring whoop and often post-tussive vomiting
 - Convalescent phase: , with recurrence of paroxysmal cough for up to 1 year
- Atypical pertussis
 - Infants: less inspiratory whoop but gagging, gasping, cyanosis, apnea and prolonged convalescent phase
 - Immunized children and adults: all stages foreshortened, often without paroxysms and without distinct stages

Clinical manifestations, atypical disease in babies

Severe and unrecognised: pertussis in UK infants

- Crowcroft et al. Arch Dis Child 2003; 88: 802-806
Inclusion:
 - n=142 infants < 5 m, admission in PICU
 - resp failure – ALTE
 - systematically specimen collection for microbiology (incl *B pertussis*)Results:
 - 23% (n=33) pertussis confirmed (PCR, culture)
 - 33% co-infection with RSV
 - n=2 cases of fatality
- Conclusion:
 - severe pertussis is “atypical” and underdiagnosed
 - clinical diagnosis is difficult
 - RSV co-infection does not exclude pertussis and can aggravate clinical course

Clinical manifestations, atypical disease in oldies

A Pertussis Outbreak Associated with Social Isolation among Elderly Nuns in a Convent

Mertens et al. Clin Infect Dis 2007; 44:266-8

- Outbreak in a Dutch convent in 1992, recognized at week 10; cohort study started at week 12. **Total: 66 cases / 75 n**
- Diagnosis: PCR, culture, significant change (3-fold) in IgG ab titres at weeks 9, 13 and 60 or single titre > 100 U/ml

- Incidence rates

- 75 retired nuns (none vaccinated) IR = 60%
 - 9 with life-long career in convent IR = 100%
 - 66 with career outside convent IR = 55% P = 0,007of which:
 - only in Dutch society IR = 74%
 - only in tropics IR = 35%
 - both IR = 17% P < 0,0001

- 24 staff members (21 vaccinated) IR = 8%

- Mortality

3/4 deaths were among nuns in age group 85-94 years

Clinical manifestations, atypical disease in oldies

A Pertussis Outbreak Associated with Social Isolation among Elderly Nuns in a Convent

Table 1. Relationship between pertussis incidence, age, and duration of isolation from society among 75 nuns with ($n = 66$) and nuns without ($n = 9$) a career outside the convent.

Group	Pertussis incidence			Duration of cough among nuns with pertussis		No. of deaths among nuns with pertussis
	No. with pertussis/total	Percentage	P for linear trend in proportions	Median days (range)	P for trend on rank	
Age group, years			.31		.20	
55–64	8/16 ^a	50		41 ^b (28–98)		1
65–74	13/21	62		67 (14–268)		0
75–84	16/27	59		51 (11–178)		0
85–94	8/11 ^a	73		83 ^b (28–236)		3
Duration of isolation from society, ^c years			.005		.72	
0–6	5/15	33		55 (28–173)		1
7–13	9/17	53		38 (14–268)		0
14–20	10/16	63		88 (11–178)		1
21–34	9/12	75		45 (30–236)		1
35–70	12/15	80		53 (14–159)		1

^a No significant difference between the incidence of pertussis in the youngest and oldest age group ($P = .21$, Fisher's exact test).

^b No significant difference between the median duration of cough in the youngest and oldest age group ($P = .10$).

^c Duration of isolation of the 9 nuns without a career outside the convent and the duration of isolation since retirement of the 66 nuns with a career outside the convent.



Discussion: waning immunity due to social isolation in women born in 1898-1936, when 100% of population experienced pertussis before 15 years of age

SHORT REPORT

Bordetella pertussis seroprevalence in Belgian adults aged 20–39 years, 2012

K. HUYGEN^{1*}, C. RODEGHIERO¹, D. GOVAERTS², I. LEROUX-ROELS³,
P. MELIN⁴, M. REYNDERS⁵, S. VAN DER MEEREN⁶,
S. VAN DEN WIJNGAERT⁷ AND D. PIERARD⁶

In the context of the Eupert-Labnet WP6 seroprevalence study (comparing sera from 14 European member states), 1500 **anonymized leftover** diagnostic samples were collected randomly during the second semester of 2012 by the laboratories of clinical biology of **six** participating **Belgian** centres, equally distributed between Flanders, Wallonia and Brussels Capital region. A total of 750 samples (125/ centre) were selected from subjects in the age group 20-29 years and 750 samples (125/ centre) from subjects in the age group 30-39 years.



Univ



Vrije Universiteit Brussel




Conclusion of seroprevalence study

Sixty-one (4%) sera were indicative of an infection in the past two years (between 50 and 100 IU/ml) and another sixty-one (4%) sera had anti-PT IgG antibodies reflecting acute infection (> 100 IU/ml).

These results highlight the presence of a *Bordetella pertussis* reservoir in the adult 'healthy' Belgian population

Laboratory diagnosis



Only *Bordetella pertussis* is included in the ECDC diagnosis of pertussis

- ***Bordetella pertussis***

Exclusively isolated from humans, as agent of whooping cough (*has also been isolated from alveolar macrophages and blood*)

- ***Bordetella parapertussis***

Pertussis-like disease (no pertussis for ECDC)
(mild cases: 20% pertussis, 40% aspecific bronchitis, 40% asymptomatic)

Also found in sheep

- ***Bordetella holmesii***

Rare cause of respiratory or not respiratory infections in humans, recently isolated from patients with pertussis-like disease

- ***Bordetella bronchiseptica***

Respiratory pathogen for and commensal of many animals, incl. dog, pig, cat & rabbit

Humans: rare cases of pertussis-like disease, opportunistic in immunodeficient patients



Vaccine-preventable diseases

News

Events

Publications

Surveillance reports

Public health developments

Scientific advances

Eurosurveillance articles

National plans

EU-IBD

EUVAcnet

Case definitions

Measles

Mumps

Rubella

Pertussis

Congenital rubella

Pertussis

Pertussis (*Bordetella pertussis*)

The case definition and classification is that stipulated by [EU Commission Decision](#) of 8 August 2012.

Clinical criteria:

Any person with a cough lasting at least two weeks and at least one of the following three:

- Paroxysms of coughing
- Inspiratory "whooping"
- Post-tussive vomiting

or

Any person diagnosed as pertussis by a physician

or

Apnoeic episodes in infants

Laboratory criteria:

At least one of the following three:

- Isolation of *Bordetella pertussis* from a clinical specimen
- Detection of *Bordetella pertussis* nucleic acid in a clinical specimen
- *Bordetella pertussis* specific antibody response

Serology results need to be interpreted according to the vaccination status

Epidemiological criteria:

Structure NRC

Two labs

→ UZ Brussel

- Diagnosis on respiratory samples (PCR; culture for strain typing)
- Most useful for young children
- Confirmation of diagnosis/strain identification for other labs

→ WIV-ISP

- Serological diagnosis (anti-PT IgG; not applicable if vaccine dosis < 1 year)
- Mostly samples from adults, generally one-point > 3 weeks symptoms

GELIEVE DIT FORMULIER MET HET STAAL OP TE STUREN NAAR:	
PCR & KWEEK en CONFIRMATIE & TYPING VAN STAMMEN	ANTI-PERTUSSIS TOXINE ANTILICHAMEN
Prof. Dr D. Pined UZ Brussel Microbiologie en Ziektenhygiëne Laarbeeklaan 101, 1090 Jette Tel.: 02477.50.00 E-mail: labmicro@uzbrussel.be	Dr. Haygen Kris WIV - ISP Dienst Immunologie Engelandstraat 642, 1180 Brussels Tel.: 02573.33.76 ; Fax: 02573.33.67 E-mail: caroline.rodegiers@wiv-isp.be

*GEGEVENS OVER HET LABORATORIUM DAT HET STAAL VERSTUURT:	VOORBEHOUDEN VOOR HET REFERENTIELABORATORIUM
Naam verantwoordelijke: Naam laboratorium: Dienst: Adres: Postcode/Woonplaats: Tel.: Fax: E-mail adres:	

*PATIËNTGEGEVENS
Naam: Geslacht: <input type="checkbox"/> M <input type="checkbox"/> V <input type="checkbox"/> onbekend Geboortedatum: Postcode/Woonplaats: Rijksregisternummer: Nationaliteit: Recent verblijf in het buitenland: <input type="checkbox"/> ja <input type="checkbox"/> nee <input type="checkbox"/> onbekend Zo ja, land of straat:

KLINISCHE GEGEVENS
Datum begin symptomen: *Hoest: <input type="checkbox"/> ja <input type="checkbox"/> nee <input type="checkbox"/> onbekend Duur van de hoest: weken dagen Vergezeld door: Paroxysmale hoestbuien: <input type="checkbox"/> ja <input type="checkbox"/> nee Giërende inspiratie ("whooping"): <input type="checkbox"/> ja <input type="checkbox"/> nee Bimken na het hoesten: <input type="checkbox"/> ja <input type="checkbox"/> nee Episoed van apnoe bij een maelgang: <input type="checkbox"/> ja <input type="checkbox"/> nee Zo ja, Geef details: Asymptomatisch contact van een bevestigd geval: <input type="checkbox"/> ja <input type="checkbox"/> nee Zo ja, geef de referenties van dit geval: Wordt de patiënt gehospitaliseerd? <input type="checkbox"/> ja <input type="checkbox"/> nee Andere symptomen: Outcome: <input type="checkbox"/> overleden datum overlijden: <input type="checkbox"/> nog steeds ziek <input type="checkbox"/> genezen <input type="checkbox"/> onbekend

*GEGEVENS OVER HET STAAL
Respiratoire monster (naar UZ Brussel te verzenden) Identificatienummer: Datum afname: Type monster: <input type="checkbox"/> nasofaryngeaal aspiraat <input type="checkbox"/> nasofaryngeaal spoeling <input type="checkbox"/> nasofaryngeaal lavage <input type="checkbox"/> nasofaryngeaal uitstrijk <input type="checkbox"/> anders (algemeen), preciezer Stam (naar UZ Brussel te verzenden) Identificatienummer: Datum isolatie: Gefoelend uit: Serum (naar WIV Engelandstraat te verzenden) Identificatienummer: Datum afname: Wordt er reeds een eerste serumstaal onderzocht <input type="checkbox"/> ja <input type="checkbox"/> nee Zo ja: Referentie: Datum:

*VACCINATIE GESCHIEDENIS
Wordt de patiënt ooit gevaccineerd: <input type="checkbox"/> ja <input type="checkbox"/> nee <input type="checkbox"/> onbekend Zo ja, hoeveel doses heeft hij gekregen: datum laatste dosis:

Naam + voornaam van de aanvragende geneesheer: Stempel van de aanvragende geneesheer:
--

*Verplicht in te vullen

NRC pertussis

Most important data

- Duration of symptoms
- Vaccination

Real-time PCR: which target for which species?

- Screening assay: IS481-IS1001

- High sensitivity: high copy number
- Low specificity

- Confirmation assay: IS1002-recA

- Lower sensitivity
- Specificity is high in combination with first assay

- At first other assays were only performed after positive result in screening

- practical difficulties
- performing both at the same time

	B. pertussis	B. parapertussis	B. holmesii	B. bronchiseptica
IS481	+++	-	++	+/-
IS1001	-	++	-	+/-
IS1002	+	+	-	+/-
recA	-	-	+	-


PCR interpretation

- Sensitivity

- IS481: 3 CFU/PCR
- IS1001: 5 CFU/PCR
- recA: 52 CFU/PCR
- IS1002: +/- 40 CFU/PCR

- Possible outcomes:

- Positive for *B. pertussis*
- Positive for *B. parapertussis*
- Positive for *B. holmesii*
- Positive for *B. species*, probably *B. pertussis* if compatible with clinical information
- Positive for *B. species*, probably *B. parapertussis* if compatible with clinical information
- undetermined (weak positive signal, which was not confirmed by repeating the test, sample should be considered as negative)





Results 2014


- **1395** cases of *B. pertussis* infection

- Serology: **930** cases
- PCR: **456** cases
- Serology + PCR: **7** cases
- **2** strains for confirmation by culture

- **94** *B. parapertussis*
- **7** *B. holmesii*




B. pertussis cases reported by the NRC




© WIV-ISP | Data source: NRC


Total number of reported pertussis cases by semester by surveillance system, 2005-2015 (first semester), Belgium.



The incidence of the reported pertussis cases by the NRC per region per 100,000, 2014, Belgium (based on 2014 Belgian population data).



Geographical distribution of reported pertussis cases by borough, 2014, Belgium (NRC, the sentinel laboratory network and the mandatory notification).



Frequency Count 6 - 17 18 - 23 26 - 29 32 - 57 60 - 98 99 - 236

Deaths due to *Bordetella (pertussis)* per age group, 2000-2012, Belgium.

	Mortality data (all <i>Bordetella</i> infections)		Minimal Clinical Dataset (<i>Bordetella pertussis</i> infections)	
	Number of recorded deaths	Age group (in years)	Number of recorded deaths	Age group (in years)
2000	1	<1	<5	65-74
2001	0	/	0	/
2002	0	/	0	/
2003	0	/	0	/
2004	1	<1	<5	<1
2005	1	<1	<5	45-64
2006	1	<1	0	/
2007	0	/	0	/
2008	0	/	<5	15-19
2009	1	<1	<5	<1
2010	1	<1	<5	<1
2011	2	<1	<5	<1
2012	1	<1	<5	<1

Ann. Inst. Pasteur Vol 20, 731-741 1906

LE MICROBE DE LA COQUELUCHE

PAR LES D^{rs} J. BORDET ET O. GENGOU

Avec la planche XXVIII.

(Travail de l'Institut Pasteur de Bruxelles.)

